Testing early treatment for tuberculosis in sepsis patients in sub-Saharan Africa
A randomized clinical trial of early empiric anti-Mycobacterium tuberculosis therapy for sepsis in sub-Saharan Africa
This study is looking at whether starting tuberculosis treatment early can help people with sepsis, especially those living with HIV in sub-Saharan Africa, survive better within 28 days.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Virginia NIH-funded |
| Lab location | 1 site (Charlottesville, United States) |
| Project ID | NIH-10867331 on NIH RePORTER |
What this research studies
This research investigates the effectiveness of starting anti-tuberculosis therapy early in patients suffering from sepsis in sub-Saharan Africa, where tuberculosis is a leading cause of bloodstream infections. The study aims to determine if administering treatment before a confirmed diagnosis can improve survival rates within 28 days. It focuses on patients, particularly those living with HIV, who are at high risk for TB sepsis, and evaluates the pharmacokinetics of anti-TB drugs in this critical population. By addressing the challenges of diagnosing TB in septic patients, the research seeks to provide timely and effective treatment.
Who could benefit from this research
Good fit: Ideal candidates for this research include adults living in sub-Saharan Africa who are experiencing sepsis and may have undiagnosed tuberculosis.
Not a fit: Patients who do not have sepsis or those who are not at risk for tuberculosis may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly reduce mortality rates among sepsis patients with tuberculosis in sub-Saharan Africa.
How similar studies have performed: Previous research has indicated that early empiric treatment for tuberculosis in septic patients can improve survival, suggesting a promising approach.
Where this research is happening
Charlottesville, United States
- University of Virginia — Charlottesville, United States (Active)
Researchers
- Principal investigator: Heysell, Scott K — University of Virginia
- Study coordinator: Heysell, Scott K
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.